CAR T-cells in Multiple Myeloma

Chimeric Antigen Receptor (CAR) T-Cell Therapy Explained! 🧬💥 Revolutionizing Cancer Treatment!Подробнее

CAR T Cells and T-Cell Therapies for CancerПодробнее

Sequencing CAR T-cells and bispecific antibodies in the treatment of multiple myelomaПодробнее

Overcoming T-cell exhaustion to improve CAR-T efficacy in multiple myelomaПодробнее

CAR T Options in MyelomaПодробнее

CAR-E: Preventing Relapse After CAR T-cell TherapyПодробнее

Phase I trial of MCARH109, a GPRC5D-directed CAR T-cell, for patients with R/R multiple myelomaПодробнее

Morning Medical Update: CAR-T Cell TherapyПодробнее

SHAPING TOMORROW THE ROLE OF CAR T IN MYELOMA CAREПодробнее

From Tick Bite to CAR-T Therapy: David Frantze's Fight Against Multiple MyelomaПодробнее

CAR-E: PREVENTING RELAPSE AFTER CAR T-CELL THERAPYПодробнее

Allogeneic CAR T Therapy for Myeloma Presentation by Swara Valsangikar at Polygence's SymposiumПодробнее

Selecting bridging therapy for patients with myeloma prior to CAR T-cell therapyПодробнее

Selinexor Prior to CAR-T Cell Therapy in Myeloma | Bruno Costa, MD | IMS 2024Подробнее

CAR-E: Preventing relapse after CAR T-cell therapyПодробнее

Update on MCARH109- a GPRC5D CAR-T Cell for Myeloma | Eric Jergens, MD | IMS 2024Подробнее

Optimizing Outcomes in Early CAR-T Therapy | Luciano Costa, MD, PhD | IMS 2024Подробнее

Clinical Trial Results for Novel Academic Anti-BCMA Myeloma CAR-T Cell | Yael Cohen, MD | IMS 2024Подробнее

An insight into the sequencing of CAR-T and bispecifics in myelomaПодробнее

How to Choose Among Similar CAR-T Therapies?/leukemia /lymphoma /Multiple myelomaПодробнее